Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease

作者：Alexa Pichet Binette, Ruben Smith, Gemma Salvadó, Pontus Tideman, Isabelle Glans, Danielle van Westen, Colin Groot, Rik Ossenkoppele, Erik Stomrud, Piero Parchi, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson, Shorena Janelidze, Sebastian Palmqvist, Oskar Hansson, Alzheimer’s Disease Neuroimaging Initiative, Olusegun Adegoke, Kedir Adem Hussen, Paul Aisen, Adeyinka Ajayi, Hannatu Amaza, Liana G. Apostolova, Miriam T. Ashford, Omobolanle Ayo, Lisa L. Barnes, Laurel Beckett, Marie Bernard, Haley Bernhardt, Virginia Boatwright, Bret Borowski, Magdalena Brylska, Neil Buckholtz, Yuliana Cabrera, Nigel J. Cairns, Maria Carrillo, Mark Choe, Taylor Clanton, Cat Conti, Hannah Craft, Karen Crawford, Sandhitsu R. Das, Charles DeCarli, Joseph Di Benedetto, Adam Diaz, Michael Donohue, Erin Drake, Claire M. Erickson, Kelley Faber, Joel P. Felmlee, Andrea Fidell, Derek Flenniken, Evan Fletcher, Juliet Fockler, Arvin Forghanian-Arani, Tatiana Foroud, Nick C. Fox, Richard Frank, Erin Franklin, Matt Glittenberg, Héctor Alfredo Baptista González, Robert C. Green, Joshua D. Grill, Jeff Gunter, Vanessa Guzmán, Kristin Harkins, Danielle Harvey, Caitie Hedberg, Lindsey Hergesheimer, Carole Ho, Isabella Hoang, John Hsiao, Clifford R. Jack, Jonathan Jackson, William Jagust, Neda Jahanshad, Cecily Jenkins, Gustavo Jiménez, Chengshi Jin, Taeho Jo, Zaven Kachaturian, Rima Kaddurah-Daouk, Kejal Kantarci, Jason Karlawish, Zaven S. Khachaturian, Alexander Knaack, Robert A. Koeppe, Magdalena Korecka, Adrienne Kormos, Kaori Kubo Germano, Winnie Kwang, Kaci Lacy, Susan Landau, Emily A. Largent, Edward B. Lee, Virginia M.‐Y. Lee, Brian J. Lopresti, Fabiola Magana, Payam Mahboubi, Ian B. Malone, Eliezer Masliah, Donna Masterman, Leonard Matoush, Melanie J. Miller, Susan Molchan, Tom Montine, John Moore-Weiss, John C. Morris, Scott Neu, Kwangsik Nho, Talia M. Nir, Rachel L. Nosheny, Kelly Nudelman, Sheila Ogwang, Ozioma Okonkwo, Shaniya Parkins, Richard J. Perrin, Ronald Petersen, Jeremy Pizzola, Zoë Potter, William Z. Potter, Gil D. Rabinovici, Michael Rafii, Rema Raman, Robert I. Reid, Calvin Reyes, Denise A. Reyes, Shannon L. Risacher, Mónica Rivera Mindt, Justin Robison, Stephanie Rossi Chen, Laurie Ryan, Pallavi Sachdev, Naomi Saito, Jennifer Salazar, Andrew J. Saykin, Christopher G. Schwarz, Mai Seng Thao, Matthew L. Senjem, Elizabeth Shaffer, Leslie M. Shaw, Li Shen, Nina Silverberg, Stephanie Smith, Peter J. Snyder, Joe Strong, Sandra Talavera, Lisa Taylor‐Reinwald, Leon J. Thal, Lisa Thomas, Sophia I. Thomopoulos, Paul Thompson, Arthur W. Toga, Duygu Tosun, John Q. Trojanowki, Diana Truran Sacrey, Prashanthi Vemuri, Victor L. Villemagne, Sarah Walter, Yang Wan, Chad Ward, Caitlin Webb, Michael W. Weiner, Trinity Weisensel, Paul A. Yushkevich, Caileigh Zimmerman · 发表于：JAMA Neurology · 年份：2025 · DOI：10.1001/jamaneurol.2025.1100 · 被引用次数：48 · 研究领域：Dementia and Cognitive Impairment Research、Alzheimer's disease research and treatments、Cancer-related cognitive impairment studies

Importance: While clinical disease stages remained largely unchanged in the 2024 update of the Alzheimer disease (AD) criteria, tau-positron emission tomography (PET) was introduced as a core biomarker and its spatial extent was incorporated into the revised biological stages of the disease. It is important to consider both the clinical and the biological stages and understand their discrepancies. Objective: To compare individuals who have discrepant biological and clinical stages with those who have congruent stages in terms of copathologies, comorbidities, and demographics. Design, Setting, and Participants: Participants were from the Swedish BioFINDER-2 (inclusion from 2017 through 2023) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) (inclusion from 2015 through 2024). BioFINDER-2 included a prospective population-based (cognitively normal [CN] older adults) and memory clinic-based cohort (participants with subjective cognitive impairment [SCD], mild cognitive impairment [MCI], and dementia). ADNI included a volunteer-based sample. All participants who were amyloid-β positive and had undergone tau-PET were included. In BioFINDER-2, 838 participants of a total of 1979 were included, and of 927 with tau-PET in ADNI, 380 were included. Exposures: The clinical (CN to dementia) and biological (based on PET; initial [amyloid-β-positive only] to advanced [amyloid-β-positive, elevated, and widespread tau]) stages from the revised AD criteria. Main Outcomes and Measures...